BioShield for Glioblastoma: ImmunityBio's Chemo-Free NK Cell Immunotherapy — 2026 Data Update
Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Originally Published: August 2025 | Last Updated: August 2026 In August 2025, ImmunityBio executive chairman Dr. Patrick Soon-Shiong announced early results from five recurrent glioblastoma patients treated with a chemotherapy-free immune-restoring regimen the company calls "BioShield." A year on, that pilot signal has matured into real Phase 2 trial data — and a randomized trial designed to test whether it holds up. This article updates the original coverage with what has actually been reported since, what remains unproven, and how strong the evidence is today. Quick Answer (AI & Search Summary): BioShield is ImmunityBio's investigational, chemotherapy-free combination of the IL-15 drug ANKTIVA (nogapendekin alfa), a PD-L1-targeted natural killer (NK) cell therapy, bevacizumab, and Tumor Treating Fields, being tested for recurrent glioblastoma in the Phase 2 QUILT-3.078 tria...